4.7 Article

Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy

期刊

出版社

BMJ PUBLISHING GROUP
DOI: 10.1136/jitc-2022-004688

关键词

immunotherapy; tumor biomarkers; translational medical research

资金

  1. Bristol Myers Squibb through its International Immuno-Oncology Network
  2. US National Institutes of Health [CA121113, CA 9071-40]
  3. Maryland Department of Health and Mental Hygiene (Cigarette Restitution Fund Program)
  4. ECOG-ACRIN Thoracic Malignancies Integrated Translational Science Center [UG1CA233259]
  5. Bloomberg-Kimmel Institute for Cancer Immunotherapy
  6. V Foundation
  7. Swim Across America
  8. LUNGevity Foundation
  9. Johns Hopkins Research Program in Quantitative Sciences
  10. Pearl M. Stetler Research Fund
  11. Emerson Collective

向作者/读者索取更多资源

Through machine learning, this study integrated the dynamics of peripheral blood immune cell subsets and predicted clinical outcomes for 239 patients with metastatic non-small cell lung cancer. The findings suggest that the integrated dynamics of peripheral blood cell counts, particularly changes in NLR, can predict therapeutic response better than traditional biomarkers like TMB and PD-L1 expression. Early changes in NLR were identified as a key predictor of treatment response.
Background Despite treatment advancements with immunotherapy, our understanding of response relies on tissue-based, static tumor features such as tumor mutation burden (TMB) and programmed death-ligand 1 (PD-L1) expression. These approaches are limited in capturing the plasticity of tumor-immune system interactions under selective pressure of immune checkpoint blockade and predicting therapeutic response and long-term outcomes. Here, we investigate the relationship between serial assessment of peripheral blood cell counts and tumor burden dynamics in the context of an evolving tumor ecosystem during immune checkpoint blockade. Methods Using machine learning, we integrated dynamics in peripheral blood immune cell subsets, including neutrophil-lymphocyte ratio (NLR), from 239 patients with metastatic non-small cell lung cancer (NSCLC) and predicted clinical outcome with immune checkpoint blockade. We then sought to interpret NLR dynamics in the context of transcriptomic and T cell repertoire trajectories for 26 patients with early stage NSCLC who received neoadjuvant immune checkpoint blockade. We further determined the relationship between NLR dynamics, pathologic response and circulating tumor DNA (ctDNA) clearance. Results Integrated dynamics of peripheral blood cell counts, predominantly NLR dynamics and changes in eosinophil levels, predicted clinical outcome, outperforming both TMB and PD-L1 expression. As early changes in NLR were a key predictor of response, we linked NLR dynamics with serial RNA sequencing deconvolution and T cell receptor sequencing to investigate differential tumor microenvironment reshaping during therapy for patients with reduction in peripheral NLR. Reductions in NLR were associated with induction of interferon-gamma responses driving the expression of antigen presentation and proinflammatory gene sets coupled with reshaping of the intratumoral T cell repertoire. In addition, NLR dynamics reflected tumor regression assessed by pathological responses and complemented ctDNA kinetics in predicting long-term outcome. Elevated peripheral eosinophil levels during immune checkpoint blockade were correlated with therapeutic response in both metastatic and early stage cohorts. Conclusions Our findings suggest that early dynamics in peripheral blood immune cell subsets reflect changes in the tumor microenvironment and capture antitumor immune responses, ultimately reflecting clinical outcomes with immune checkpoint blockade.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据